| dc.creator | Fregnani | |
| dc.creator | Eduardo R.; da Cruz Perez | |
| dc.creator | Danyel E.; de Almeida | |
| dc.creator | Oslei Paes; Fonseca | |
| dc.creator | Felipe Paiva; Soares | |
| dc.creator | Fernando A.; Castro-Junior | |
| dc.creator | Gilberto; Alves | |
| dc.creator | Fabio A. | |
| dc.date | 2017 | |
| dc.date | fev | |
| dc.date | 2017-11-13T13:56:40Z | |
| dc.date | 2017-11-13T13:56:40Z | |
| dc.date.accessioned | 2018-03-29T06:10:00Z | |
| dc.date.available | 2018-03-29T06:10:00Z | |
| dc.identifier | Histopathology. Wiley-blackwell, v. 70, p. 473 - 484, 2017. | |
| dc.identifier | 0309-0167 | |
| dc.identifier | 1365-2559 | |
| dc.identifier | WOS:000394985800015 | |
| dc.identifier | 10.1111/his.13095 | |
| dc.identifier | http://onlinelibrary-wiley-com.ez88.periodicos.capes.gov.br/doi/10.1111/his.13095/full | |
| dc.identifier | http://repositorio.unicamp.br/jspui/handle/REPOSIP/329912 | |
| dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1366937 | |
| dc.description | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
| dc.description | The aim of this study was to investigate whether the expression of BRAF-V600E determines an aggressive clinical and molecular presentation of ameloblastoma. Methods and results: Ninety-three cases of solid ameloblastomas were arranged in a 1.0-mm tissue microarray (TMA) block. Immunohistochemistry against a large panel of cytokeratins (CK), epidermal growth factor receptor (EGFR), parathyroid hormone-related peptide (PTHrP), syndecan-1, Ki67, p53 and BRAF-V600E were performed. Clinicopathological parameters, including sex, age, tumour size, tumour duration, tumour location, treatment, recurrences, radiographic pattern, vestibular/lingual and basal cortical plates disruption and follow-up data, were obtained from patients' medical records. Immuno-expression of BRAF-V600E was investigated in 73 cases that remained available in TMA sections. Our results indicated that 46.6% (34 cases) demonstrated cytoplasm positivity (six weak and 28 strong positivity). BRAF-V600E expression was associated significantly with the expression of CK8 (P = 0.00077), CK16 (P = 0.05), PTHrP (P = 0.0082) and p53 (P = 0.0087). Additionally, a significant association was seen with the presence of recurrences (P = 0.0008), multilocular radiographic appearance (P = 0.044) and disruption of basal bone cortical (P = 0.05). Univariate analysis showed that BRAF-positive cases (P = 0.001), EGFR-negative/weak positive cases (P = 0.03) and multilocular tumours (P = 0.04) had a significantly lower disease-free survival rate, but these parameters were not considered independent prognostic factors in the multivariate analysis (P > 0.05). Conclusions: Our findings suggest an association of BRAF-V600E with parameters of a more aggressive behaviour of ameloblastoma, supporting the future use of BRAF inhibitors for targeted therapy of this neoplasm. | |
| dc.description | 70 | |
| dc.description | 3 | |
| dc.description | 473 | |
| dc.description | 484 | |
| dc.description | Sao Paulo State Research Foundation (FAPESP/Brazil) | |
| dc.description | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
| dc.language | English | |
| dc.publisher | Wiley-Blackwell | |
| dc.publisher | Hoboken | |
| dc.relation | Histopathology | |
| dc.rights | fechado | |
| dc.source | WOS | |
| dc.subject | Ameloblastoma | |
| dc.subject | Braf | |
| dc.subject | Mitogen-activated Protein Kinase | |
| dc.subject | Odontogenic Tumours | |
| dc.title | Braf-v600e Expression Correlates With Ameloblastoma Aggressiveness | |
| dc.type | Artículos de revistas | |
